Tīmeklis2024. gada 3. okt. · H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Axsome Therapeutics (AXSM - Research Report) today and set a price target of … TīmeklisH.C. Wainwright analyst Ram Selvaraju points in the direction of Sorrento Therapeutics , as one such company. Selvaraju rates SRNE a Buy along with a $30 price target, …
Sorrento: Covid-19 Tests Could Generate Significant Revenue, Says Analyst
Tīmeklis2024. gada 28. dec. · Sorrento Therapeutics ( SRNE) might not receive widespread coverage on Wall Street, but one analyst has repeatedly banged the drum for the drug maker. H.C. Wainwright’s Ram Selvaraju thinks SRNE shares are significantly undervalued. Backing his Buy rating with a $26 price target, the analyst sees shares … Tīmeklispirms 1 dienas · I, Raghuram Selvaraju, Ph.D. and Boobalan Pachaiyappan, Ph.D. , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities ... red stag salt lake city
Inovio: Advaccine Deal Is a Positive but Not a Game Changer, Analyst …
Tīmeklis2024. gada 23. sept. · In a Sept. 21 research note, H.C. Wainwright analyst Ram Selvaraju reported that Equillium Inc. (EQ:NASDAQ) received approval from the U.S. Food and Drug Administration (FDA) to advance its COVID-19 clinical trial.. Selvaraju relayed what is now known about the program. Equillium intends to launch a global … Tīmeklis2024. gada 28. dec. · H.C. Wainwright’s Ram Selvaraju thinks SRNE shares are significantly undervalued. Backing his Buy rating with a $26 price target, the analyst … Tīmeklis2024. gada 10. apr. · H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Verona Pharma today and set a price target of $32.00. The company’s shares closed last Thursday at $20.53. red stag shoes